Table 1.
Associations between PD-L1, clinicopathological characteristics, and other immune cells in PESCC.
| Characteristic | PD-L1 negative | PD-L1 positive | a p value |
|---|---|---|---|
| No. of patients | No. of patients | ||
| Sex | 0.179 | ||
| Male | 38 | 23 | |
| Female | 16 | 4 | |
| Age | 0.465 | ||
| ≤60 | 22 | 8 | |
| >60 | 32 | 19 | |
| Location | 0.681 | ||
| Upper third | 4 | 3 | |
| Middle and lower thirds | 50 | 24 | |
| bT classification | 0.811 | ||
| T1-T2 | 21 | 12 | |
| T3-T4 | 33 | 15 | |
| bN classification | 0.220 | ||
| N0 | 16 | 12 | |
| N1 | 38 | 15 | |
| bM classification | 0.742 | ||
| M0 | 45 | 24 | |
| M1 | 9 | 3 | |
| bStage | 0.472 | ||
| I-II | 20 | 13 | |
| III-IV | 34 | 14 | |
| Necrosis | 0.865 | ||
| No | 37 | 19 | |
| Yes | 17 | 8 | |
| First treatment | 0.518 | ||
| Surgery | 29 | 16 | |
| Chemoradiotherapy | 5 | 4 | |
| Chemotherapy | 20 | 7 | |
| cTIIs | <0.001 | ||
| Poor | 38 | 7 | |
| Rich | 16 | 20 | |
| CD4 | 0.023 | ||
| Poor | 41 | 13 | |
| Rich | 13 | 14 | |
| CD8 | 0.002 | ||
| Poor | 45 | 13 | |
| Rich | 9 | 14 | |
| CD163 | <0.001 | ||
| Poor | 44 | 11 | |
| Rich | 10 | 16 |
aFisher's test; bTNM stage: the AJCC (8th edition) was used; cTIIs: tumor-infiltrating immune cells.